Original Research
Published on 28 Oct 2022
OMIXCARE: OMICS technologies solved about 33% of the patients with heterogeneous rare neuro-developmental disorders and negative exome sequencing results and identified 13% additional candidate variants
in Molecular and Cellular Pathology
- 4,221 views
- 14 citations